New: Compliance Automation Reduces Risk and Time Pharma Solutions is the exclusive partner and distributor of LighthouseAI™, a comprehensive AI-based compliance solution to mitigate risk and manage the rapid pace of regulatory change while reducing the time and cost...
Minnesota Board of Pharmacy Fee is a Barrier to Entry
The 2,200% increase for Minnesota fees has created an unprecedented barrier to entry for small wholesalers and start-up manufacturers. Of our clients, 25% have decided to forego licensure in the state– typically smaller wholesalers and virtual manufacturers who have not yet started a business within the state.
Drug Pricing Transparency Fight Rages On
Even as the COVID-19 pandemic disrupts day-to-day life, drug pricing transparency rages on between consumer groups, regulators, and industry. Regulators are now having to resort to assessing significant fines to increase compliance.
2020 Update: Continuing Pressure on Drug Manufacturers
With the developments around COVID-19, the drug manufacturers that working on a cure for the virus have been praised as (potential) saviors across the globe. This is a stark change to how they have regarded over the last few years – drug manufacturers have faced significant scrutiny due to a variety of issues including the opioid epidemic, generic price-fixing and price increases.
How Telemedicine Has Made Generic Drugs Sexy
How Telemedicine Has Made Generic Drugs Sexy Since 2017, Direct-to-Consumer (DTC) startups (some engaged by Pharma Solutions!) have cropped up to...
Nevada Levies $17.4 Million in Fines on Diabetes Drug Manufacturers
The State of Nevada shocked the pharmaceutical supply chain last month by levying an unprecedented $17.4 million in fines due to deficient reporting by drug manufacturers of prescription drugs that are essential for treating diabetes in Nevada.
A Generic Manufacturer’s Current Pressures and Opportunities
Consolidation of purchase power in the past 20 years has dramatically changed the landscape for generic manufacturers; and recent events are making it worse: active prosecution for price-fixing, the FDA recently announcing a wave of unannounced FDA audits, and blame for the Opioid Epidemic. So what is a generic manufacturer to do? There are opportunities still available for a generic manufacturer to increase their top and bottom lines.